Brain Tumor Small Molecule Drug Development Services

Small molecule drugs can reach intracellular or extracellular targets of immune cells involved in specific immune pathways, enhance antitumor immunity, or reduce immunosuppression. Brain tumor small molecule drugs also have potential complementary or synergistic effects with existing immunotherapies. Compared to therapeutic antibodies, small molecule drugs have greater penetration into the tissue and tumor microenvironment (TME). It can cross physiological barriers such as the blood-brain barrier, providing new options for the treatment of brain tumors and brain metastases.

Ssmall molecule drugs for brain tumor

Brain tumor small molecule inhibitor development

Small molecule inhibitors are a class of biologically active small molecule compounds. Compared to most antibodies, small molecules can easily penetrate tissues. Therefore, they can target extracellular and intracellular targets to promote the anti-brain tumor process. Alfa Oncology is continuously developing new brain tumor-related genes, such as CREPT, which has been reported to promote cell cycle transition, promote tumorigenesis, and is a highly promising target for cancer therapy.

Based on this background, we identified a class of genes like CREPT as targets for anti-brain tumor drugs. We screen and synthesize small molecule inhibitors that specifically target binding, thus assisting our customers in developing drugs related to brain tumor inhibition and other research. We believe that this will be a novel anti-brain tumor small molecule drug with a new target, a new molecule, and a new mechanism of action.

Brain tumor drug delivery system development

Even small molecules do not exhibit the desired distribution within an organism, thus requiring the use of delivery systems that carry therapeutic agents. In response to this urgent need and significant challenge, Alfa Oncology has taken a major step forward in the development of a drug delivery system for brain tumors. We offer our customers four development options, nanoparticle-based, microchip-based, bacterial-based, and exosome-based.

We explore the possible routes of drug delivery across the blood-brain barrier to the brain tumor lesion site in several ways. We design targeted drug delivery systems applicable to different physiological and pathological characteristics according to the pattern of brain tumor occurrence and progression. We aim to deliver the right number of drugs to the right location at the right time. This increases the efficiency of drug utilization, effectively improves the targeting and therapeutic effect of brain tumors, and reduces toxic side effects.

Category: General